Compare · ECOR vs ITGR
ECOR vs ITGR
Side-by-side comparison of electroCore Inc. (ECOR) and Integer Holdings Corporation (ITGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and ITGR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $4.26B, about 49.9x ECOR ($85.4M).
- ITGR has been more active in the news (16 items in the past 4 weeks vs 7 for ECOR).
- ITGR has more recent analyst coverage (23 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- Integer Holdings Corporation
- Price
- -
- -
- Market cap
- $85.4M
- $4.26B
- 1M return
- -
- +24.90%
- 1Y return
- -
- +15.30%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 16
- Recent ratings
- 2
- 23
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Latest ECOR
- CFO and Interim President Lev Joshua S. exercised 20,000 shares at a strike of $4.50 and sold $200,120 worth of shares (20,000 units at $10.01) (SEC Form 4)
- electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
- Director Errico Thomas J. bought $49,272 worth of shares (5,000 units at $9.85), increasing direct ownership by 1% to 343,332 units (SEC Form 4)
- SEC Form 10-Q filed by electroCore Inc.
- electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- electroCore Announces Second Quarter 2026 Financial Results
- electroCore to Participate in Upcoming Investor Conferences
- electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
- SEC Form DEF 14A filed by electroCore Inc.
- New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
Latest ITGR
- SEC Form DEFA14A filed by Integer Holdings Corporation
- INTEGER HOLDINGS: Kaskela Law Announces Probe into Adequacy of $127.00 Per Share Buyout Price – Fair or Inadequately Low for the Company’s Shareholders?
- SEC Form 10-Q filed by Integer Holdings Corporation
- SEC Form DEFA14A filed by Integer Holdings Corporation
- Integer Holdings Corporation filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form DEFA14A filed by Integer Holdings Corporation
- SEC Form DEFA14A filed by Integer Holdings Corporation
- SEC Form DEFA14A filed by Integer Holdings Corporation
- SEC Form DEFA14A filed by Integer Holdings Corporation
- SEC Form DEFA14A filed by Integer Holdings Corporation